New Drug Could Cut ‘Bad’ Cholesterol Nearly in Half

It outperformed a drug from Merck


New Drug Could Cut ‘Bad’ Cholesterol Nearly in Half

injection shot in the arm booster stocks 630 300x214 New Drug Could Cut 'Bad' Cholesterol Nearly in HalfShares of Regeneron Pharmaceuticals (REGN) climbed almost 4% in Wednesday morning trading after a late stage trial of a new cholesterol drug showed promising results.

Alirocumab, developed in partnership with Sanofi (SNY), is an injectable drug designed to combat LDL cholesterol by attacking PCSK9, a key protein. The drug had been previously tested reducing LDL cholesterol by 70% when administered in combination with other treatments. In the new study, the drug reduced LDL cholesterol by 47% when used by itself, Reuters noted.

MerckPromo New Drug Could Cut 'Bad' Cholesterol Nearly in Half
Merck to Cut Thousands of Jobs in Cost-Cutting Move

Analysts say that injectable cholesterol drugs like Alirocumab could generate revenue of $3 billion a year.

Included in the study were some patients who were only administered Merck‘s (MRK) Zetia cholesterol drug. Patients taking Zetia saw a 15.6% decline in cholesterol levels during the study.

Shares of Sanofi rose slightly in Wednesday morning trading, while Merck moved up almost 1%.

Article printed from InvestorPlace Media,

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.